Fierce Pharma Asia—BeiGene-Novartis PD-1 deal; Sinovac vaccine; Celltrion antibody COVID-19 data
Novartis paid approximately $2.2 billion for BeiGene's China-approved PD-1 drug tislelizumab to match its own checkpoint inhibitor. Hear what ...
Novartis paid approximately $2.2 billion for BeiGene's China-approved PD-1 drug tislelizumab to match its own checkpoint inhibitor. Hear what ...
Copyright © 2021 Infiniti CS News
Copyright © 2021 Infiniti CS News